Literature DB >> 27905836

Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era.

Sevgen Tanır Basaranoglu1, Eda Karadag Oncel1, Kubra Aykac1, Yasemin Ozsurekci1, Ali Bülent Cengiz1, Ates Kara1, Mehmet Ceyhan1.   

Abstract

A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received ≥ 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.

Entities:  

Keywords:  Streptococcus pneumoniae; antibiotic resistance; breakthrough infection; invasive pneumococcus disease; surveillance; vaccination; vaccine failure

Mesh：

Substances：

Year:  2016        PMID： 27905836      PMCID： PMC5404356          DOI： 10.1080/21645515.2016.1256519

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  9 in total

1.  Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Children in France.

Authors:  Cécile Godot; Corinne Levy; Emmanuelle Varon; Capucine Picard; Fouad Madhi; Robert Cohen
Journal:  Pediatr Infect Dis J       Date:  2015-10       Impact factor: 2.129

2.  Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).

Authors:  Ronald N Jones; Helio S Sader; Rodrigo E Mendes; Robert K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 2.803

3.  Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children.

Authors:  Emmanuelle Varon; Robert Cohen; Stéphane Béchet; Catherine Doit; Corinne Levy
Journal:  Vaccine       Date:  2015-10-21       Impact factor: 3.641

4.  European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era.

Authors:  Adoración Navarro Torné; Joana Gomes Dias; Chantal Quinten; Frantiska Hruba; Marta Cecilia Busana; Pier Luigi Lopalco; Andrew J Amato Gauci; Lucia Pastore-Celentano
Journal:  Vaccine       Date:  2014-05-02       Impact factor: 3.641

5.  Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide.

Authors:  Mehmet Ceyhan; Nezahat Gurler; Akgun Yaman; Candan Ozturk; Lutfiye Oksuz; Sengul Ozkan; Melike Keser; Nuran Salman; Emre Alhan; Duygu Esel; Meral Gultekin; Yildiz Camcioglu; Mustafa Gul; Yelda Sorguc; Sohret Aydemir; Murat Gunaydin; Yusuf Yakupogullari; Ahmet Kizirgil
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

6.  Invasive pneumococcal infections among vaccinated children in the United States.

Authors:  Sarah Y Park; Chris A Van Beneden; Tamara Pilishvili; Michael Martin; Richard R Facklam; Cynthia G Whitney
Journal:  J Pediatr       Date:  2009-12-03       Impact factor: 4.406

7.  Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014.

Authors:  Mehmet Ceyhan; Yasemin Ozsurekci; Nezahat Gürler; Lütfiye Öksüz; Sohret Aydemir; Sengul Ozkan; Serife Yuksekkaya; Melike Keser Emiroglu; Meral Gültekin; Akgün Yaman; Abdurrahman Kiremitci; Keramettin Yanık; Arzu Karli; Hatice Ozcinar; Faruk Aydin; Gulcin Bayramoglu; Yasemin Zer; Zeynep Gulay; Efgan Dogan Gayyurhan; Mustafa Gül; Cüneyt Özakın; Hüseyin Güdücüoğlu; Duygu Perçin; Nezahat Akpolat; Candan Ozturk; Yıldız Camcıoğlu; Eda Karadağ Öncel; Melda Çelik; Laser Şanal; Hakan Uslu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 8.  A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis.

Authors:  Myint Tin Tin Htar; Harish Madhava; Paul Balmer; Dina Christopoulou; Damianos Menegas; Eric Bonnet
Journal:  Adv Ther       Date:  2013-09-03       Impact factor: 3.845

9.  Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Authors:  Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore
Journal:  PLoS Med       Date:  2013-09-24       Impact factor: 11.069
  9 in total
  3 in total

1.  One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-vaccine era.

Authors:  Gulnihan Ustundag; Eda Karadag-Oncel; Sebahat Sen-Tas; Ahu Kara-Aksay; Dilek Yilmaz-Ciftdogan; Nisel Yilmaz; Mehmet Ceyhan
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

2.  Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain.

Authors:  Sergi Hernández; Fernando Moraga-Llop; Alvaro Díaz; Mariona F de Sevilla; Pilar Ciruela; Carmen Muñoz-Almagro; Gemma Codina; Magda Campins; Juan José García-García; Cristina Esteva; Conchita Izquierdo; Sebastià González-Peris; Johanna Martínez-Osorio; Sonia Uriona; Luis Salleras; Ángela Domínguez
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

3.  Serotype distribution of Streptococcus pneumonia in children with invasive disease in Turkey: 2015-2018.

Authors:  Mehmet Ceyhan; Kubra Aykac; Nezahat Gurler; Yasemin Ozsurekci; Lütfiye Öksüz; Özlem Altay Akısoglu; Fatma Nur Öz; Melike Emiroglu; Hatice TurkDagi; Akgün Yaman; Güner Söyletir; Candan Öztürk; Nezahat Akpolat; Cüneyt Özakin; Faruk Aydın; Şöhret Aydemir; Abdurrahman Kiremitci; Meral Gültekin; Yıldız Camcıoglu; Yasemin Zer; Hüseyin Güdücüoğlu; Zeynep Gülay; Asuman Birinci; Cigdem Arabaci; Adem Karbuz; Ilker Devrim; Yelda Sorguc; Betil Özhak Baysan; Eda Karadag Oncel; Nisel Yilmaz; Yasemin Ay Altintop
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.